Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
about
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromesMyelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementPP2A: The Achilles Heal in MDS with 5q DeletionPP2A: The Wolf in Sheep's Clothing?Established and emerging targeted therapies in the myelodysplastic syndromes.Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-AnalysisClinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesRibosomal Protein Mutations Result in Constitutive p53 Protein Degradation through Impairment of the AKT PathwayLarge-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications.Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.The myelodysplastic syndromes: the era of understanding.Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.RP-MDM2-p53 Pathway: Linking Ribosomal Biogenesis and Tumor Surveillance.Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.
P2860
Q26778754-F6241BC9-2BDD-4CDA-B5BF-3CC46FCDA9C8Q26796240-89B22878-672E-4B3F-804A-8FAF9AD0E150Q27690852-FB193D95-3A4D-458A-8236-E43AFF72E029Q28088747-D0EF70BF-A911-4BD1-ACFC-EDDF593D8C46Q30245476-F1A539F3-2D39-412D-97DC-B1D213665F03Q33424228-C1C4C0CF-45A8-45FA-AE52-EB789A519367Q33436627-C48D3F7B-4747-4477-88B5-D8019E721D90Q33836662-886CE06F-9C72-4381-B63D-CC3B0395E44BQ34783754-2A7D48F7-200B-4A77-A5FE-997BF187433CQ35680232-2337DED6-D1AA-41A6-B9B3-1775EFD3D6A8Q36309654-A353D3DE-779C-44BB-B588-219772E4AE73Q37094962-D09FF5D6-39B7-4C69-AB6B-C244D88658F7Q38245878-97407EED-08F9-4D77-8B9C-5F1F21F0AD81Q38415206-32027B93-A2AB-4E39-AABD-642BEF89FAF9Q38857091-B957EE37-349C-4924-9B12-D9993C470F43Q39240258-CFEA8DFA-63E1-45EC-AC2B-0F62C35DF056Q39413114-43DAD506-3E1C-450E-98BC-B90BFA45C8F7Q39456968-EFDCA10C-7C6F-46B5-B774-FC4EE132824FQ40420210-73B24454-D65F-42D6-AAEA-68C95DE265E9Q40608642-C1B19C45-0F24-4CA1-9B11-47CCBCBA0557Q41156034-4B31DDAD-853C-42E6-A720-CC7DE1C6D7C6Q43428613-BFE4B148-D388-4EF7-B942-DD6FB1B79737Q47548041-E6C1FA10-628D-4923-A7E1-0D04D5BE7F7AQ54602748-3179253C-1F93-47FD-B77F-788C9493C582
P2860
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Extended survival and reduced ...... s with lower-risk del(5q) MDS.
@ast
Extended survival and reduced ...... s with lower-risk del(5q) MDS.
@en
type
label
Extended survival and reduced ...... s with lower-risk del(5q) MDS.
@ast
Extended survival and reduced ...... s with lower-risk del(5q) MDS.
@en
prefLabel
Extended survival and reduced ...... s with lower-risk del(5q) MDS.
@ast
Extended survival and reduced ...... s with lower-risk del(5q) MDS.
@en
P2093
P2860
P356
P1433
P1476
Extended survival and reduced ...... s with lower-risk del(5q) MDS.
@en
P2093
A Giagounidis
J M Bennett
J M Shammo
M A Sekeres
MDS-003 Study Investigators
R D Knight
P2860
P2888
P304
P356
10.1038/LEU.2013.305
P577
2013-10-22T00:00:00Z
P5875
P6179
1016009452